ZYUS Life Sciences Corporation (TSXV:ZYUS)
Canada · Delayed Price · Currency is CAD 0.4950
+0.0450 (10.00%)
At close: May 6, 2026
ZYUS Life Sciences Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.12 | 0.23 | 1.9 | 3.98 | 0.21 | 6.3 |
Short-Term Investments | - | - | - | 1.87 | - | 2.3 |
Cash & Short-Term Investments | 0.12 | 0.23 | 1.9 | 5.85 | 0.21 | 8.59 |
Cash Growth | -82.20% | -87.75% | -67.50% | 2660.38% | -97.53% | 1.69% |
Accounts Receivable | 0.34 | 0.29 | 0.37 | 0.63 | 0.24 | - |
Other Receivables | - | - | - | - | - | 0.04 |
Total Trade Receivables | 0.34 | 0.29 | 0.37 | 0.63 | 0.24 | 0.04 |
Inventory | 0.25 | 0.34 | 0.63 | 2.04 | 4.2 | - |
Other Current Assets | 0.21 | 0.28 | 0.46 | 0.87 | 1.61 | - |
Total Current Assets | 0.91 | 1.14 | 3.36 | 9.39 | 6.27 | 8.64 |
Net Property, Plant & Equipment | 3.63 | 3.8 | 11.16 | 13.89 | 17.03 | 0 |
Other Intangible Assets | - | - | - | 12.32 | 35.39 | - |
Goodwill | - | - | - | 5.87 | 5.87 | - |
Other Long-Term Assets | 0.14 | 0.14 | 0.15 | 0.15 | 0.16 | - |
Total Assets | 4.67 | 5.08 | 14.67 | 41.63 | 64.71 | 8.64 |
Accounts Payable | 6.68 | 10.26 | 7.86 | 6.69 | 13.04 | 0.1 |
Short-Term Debt | 9.38 | 0.89 | 9.12 | 6.15 | 0.9 | - |
Current Portion of Leases | 0.34 | 0.34 | 0.41 | 0.4 | 0.33 | - |
Total Current Liabilities | 16.4 | 11.49 | 17.38 | 13.24 | 14.27 | 0.1 |
Long-Term Debt | 10.5 | 12.91 | 0.37 | 0.64 | 30.8 | - |
Long-Term Leases | 1.73 | 1.81 | 2.27 | 2.62 | 2.88 | - |
Other Long-Term Liabilities | - | - | - | 2.02 | 12.03 | - |
Total Long-Term Liabilities | 12.22 | 14.71 | 2.64 | 5.27 | 45.7 | - |
Total Liabilities | 28.62 | 26.2 | 20.02 | 18.51 | 59.97 | 0.1 |
Common Stock | 159.83 | 159.61 | 156.7 | 154.09 | 92.67 | 4.66 |
Additional Paid-in Capital | 14.12 | 13.99 | 10.96 | 9.2 | 9.05 | 0.45 |
Accumulated Other Comprehensive Income | 0.88 | 1 | 0.99 | 0.01 | 0.61 | - |
Retained Earnings | -198.79 | -195.72 | -173.99 | -140.19 | -97.6 | 3.42 |
Shareholders' Equity | -23.95 | -21.12 | -5.34 | 23.11 | 4.74 | 8.54 |
Total Liabilities & Equity | 4.67 | 5.08 | 14.67 | 41.63 | 64.71 | 8.64 |
Total Debt | 21.94 | 15.94 | 12.16 | 9.81 | 34.9 | 0 |
Net Cash (Debt) | -21.83 | -15.7 | -10.26 | -3.95 | -34.69 | 8.59 |
Net Cash Growth | - | - | - | - | - | 1.69% |
Net Cash Per Share | -0.28 | -0.20 | -0.14 | -0.07 | -0.90 | 1.71 |
Book Value | -23.95 | -21.12 | -5.34 | 23.11 | 4.74 | 8.54 |
Book Value Per Share | -0.31 | -0.27 | -0.07 | 0.41 | 0.12 | 1.70 |
Tangible Book Value | -23.95 | -21.12 | -5.34 | 4.92 | -36.52 | 8.54 |
Tangible Book Value Per Share | -0.31 | -0.27 | -0.07 | 0.09 | -0.95 | 1.70 |